Initiation of warfarin treatment in outpatients with nonrheumatic atrial fibrillation: A scheme for early indication of maintenance dose

Clinical and Applied Thrombosis/Hemostasis

Volumn 4, Issue 4, 1998, Pages 274-276

  Pengo, Vittorio ^a   Zasso, Antonella ^a   Barbero, Fabio ^a   Biasiolo, Allesandre ^a   Rampazzo, Patrizia ^a   Brocco, Tania ^a  

^a UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

Author keywords

INR; Oral anticoagulants; Warfarin

Indexed keywords

WARFARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CONTROLLED STUDY; DOSE CALCULATION; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROTHROMBIN TIME; REGRESSION ANALYSIS; THROMBOEMBOLISM;

EID: 0031716206     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/107602969800400411     Document Type: Article

References (20)

1. Dalen JE, Hirsh J, eds. Third ACCP Consensus Conference on Antithrombotic Therapy. Chest 1992;102:303S.
2. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet 1989;1:175.
3. Stroke Prevention in Atrial Fibrillation Study Group Investigators. Stroke prevention in atrial fibrillation study. Final results. Circulation 1991;84:527.
4. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 1990; 323:1505.
5. Connolly SJ, Laupacis A, Gent M, et al. Canadian atrial fibrillation study. J Am Coll Cardiol 1991;8:49.
6. Ezekowitz MD, Bridgers SL, James KE, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. N Engl J Med 1992;327:1406.
7. Kulbertus HE, Leval-Rutten FD, Bartsch P, et al. Atrial fibrillation in the elderly ambulatory patients. In: Kulbertus HE, Olsson SB, Schlepper M, eds., Atrial fibrillation Molndal, AB Hassle, Kiruna, Sweden 1992:148.
8. Lake FR, McCall MG, Cullen KJ, et al. Atrial fibrillation and mortality in an elderly population. Austr NZJ Med 1989;19:321.
9. Hirsh J, Dalen JE, Deykin D, et al. Oral anticoagulants. Mechanism of action, clinical effectiveness and optimal therapeutic range. Chest 1995;108:231S.
10. British Society of Haematology, British Committee for Standards in Haematology, Haemostasis and Thrombosis Task Force. Guidelines on oral anticoagulation: second edition. J Clin Pathol 1990; 43:177.
11. Holford NHG. Clinical pharmacokinctics and pharmacodynamics of warfarin: understanding the dose-effect relationship. Clin Pharmacokin 1986;11:483.
12. Fennerty A, Dolben J, Thomas P, et al. Flexible induction dose regimen for warfarin and prediction of maintenance dose. BMJ 1984;288:1268.
13. Shetty HGM, Fennerty AG, Routledge PA. Clinical pharmacokinetic considerations in the control of oral anticoagulant therapy. Clin Pharmacokin 1989;16:238.
14. Flegel KM, Hanley J. Risk factors for stroke and other embolic events in patients with nonrheumatic atrial fibrillation. Stroke 1989;20:1000.
15. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke 1991; 22:983.
16. Wolf PA, Abbott RD, Kannel WB: Atrial fibrillation: a major contributor to stroke in the elderly: the Framingham Study. Arch Intern Med 1987;147:1561.
17. Kannel WB, Abbott RD, Savage DD, et al. Epidemiologic features of chronic atrial fibrillation: the Framingham Study. N Engl J Med 1982;306:1019.
18. James AH, Britt RP, Raskino CL, et al. Factors affecting the maintenance dose of warfarin. J Clin Pathol 1992;45:704.
19. Redwood M, Taylor C, Bain BJ, et al. The association of age with dosage requirement for warfarin. Age Aging 1991;20:217.
20. Doi SAR. Pharmacodynamic optimization of warfarin therapy. Clin Pharmacol Ther 1994;55:597.